EU And Japan Expansion Will Leverage Aging Population Trends

Key Takeaways

• Accelerating Pepaxti sales, positive market trends, and strict cost controls position the company for sustainable growth and improving margins.
  
• Expansion efforts and pipeline development create multiple paths for future revenue and strategic partnerships.
  
• Heavy dependence on Pepaxti, ambitious sales targets, and ongoing funding needs expose Oncopeptides to high financial and competitive risks amid shifting oncology market dynamics.

Catalysts

A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally.

• Strong growth momentum in Pepaxti sales, with three consecutive quarters above 30% quarter-over-quarter growth, positive real-world data, and expanded regional access in key EU markets indicates potential to accelerate revenue and achieve cash flow positivity by 2026, especially as faster-than-expected adoption and new clinical guideline inclusion support ongoing topline expansion.
  
• The company is leveraging the demographic shift towards an aging population and increased cancer incidence, which are expanding the total addressable market for multiple myeloma therapies-supporting a runway for sustainable revenue growth and market share gains as these long-term trends play out globally.
  
• Ongoing late-stage partnership negotiations in Japan, a market with similar size and opportunity to Germany, could unlock large, non-dilutive upfront and milestone payments, double-digit royalties, and partner-led commercialization, reducing cash burn, improving net margins, and diversifying revenue streams once a deal is closed.
  
• The company's robust cost controls and stabilized operating expenses, even as revenues ramp, suggest rising operating leverage; this positions Oncopeptides to drive improved earnings and net margins as topline growth continues and fixed costs are absorbed by higher sales volumes.
  
• Expansion of their preclinical peptide-drug conjugate and NK cell engagement pipeline-within a healthcare landscape increasingly favoring precision medicine and next-generation oncology therapeutics-provides long-term optionality for multiple future revenue streams and enhances the company's strategic value for potential partnerships or M&A, supporting longer-term earnings potential.

Oncopeptides Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Oncopeptides's revenue will grow by 122.8% annually over the next 3 years.
• Analysts are not forecasting that Oncopeptides will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Oncopeptides's profit margin will increase from -525.2% to the average GB Biotechs industry of 20.4% in 3 years.
• If Oncopeptides's profit margin were to converge on the industry average, you could expect earnings to reach SEK 115.0 million (and earnings per share of SEK 0.44) by about September 2028, up from SEK -267.2 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 14.4x on those 2028 earnings, up from -4.0x today. This future PE is lower than the current PE for the GB Biotechs industry at 32.5x.
• Analysts expect the number of shares outstanding to grow by 4.91% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 4.92%, as per the Simply Wall St company report.

Oncopeptides Future Earnings Per Share Growth

Risks

• Oncopeptides' financial plan for reaching cash flow positivity by 2026 is highly dependent on maintaining an aggressive 30–40% quarter-over-quarter sales growth rate for Pepaxti across Europe; any slowdown in sales momentum-due to factors like access delays, increased competition, or market saturation-could significantly undermine revenue forecasts and delay or prevent profitability.
  
• The company's near-total reliance on Pepaxti as its sole commercial asset exposes it to severe product concentration risk; regulatory setbacks, safety concerns, adverse real-world data, or superior competing treatments could result in sharp revenue declines and material earnings volatility.
  
• Ongoing rights issues and use of a short-term credit line indicate a persistent need for external funding and a precarious cash position; if growth stalls or anticipated licensing deals (especially in Japan) do not materialize or are less lucrative than expected, Oncopeptides may face additional dilution, higher financing costs, and persistent net margin pressure.
  
• The oncology industry is rapidly evolving toward novel immunotherapies and CAR-T/bispecific approaches; Pepaxti's alkylating mechanism, while endorsed in current guidelines, may face declining relevance and market share in the long term, threatening Oncopeptides' sustainable revenue and ability to defend pricing.
  
• Long-term industry and regional healthcare trends-such as expanding pricing pressures, stricter cost-effectiveness demands from payors, and complex reimbursement environments-pose risks to Oncopeptides' ability to maintain current per-patient revenues and gross margins, especially if future competition forces price concessions in key European markets.

Valuation

• The analysts have a consensus price target of SEK5.5 for Oncopeptides based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be SEK562.4 million, earnings will come to SEK115.0 million, and it would be trading on a PE ratio of 14.4x, assuming you use a discount rate of 4.9%.
• Given the current share price of SEK4.77, the analyst price target of SEK5.5 is 13.3% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.